Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure

• US 5,958,896 A
• Filed: 08/08/1997
• Issued: 09/28/1999
• Est. Priority Date: 08/08/1997
• Status: Expired due to Term

• Current Assignee: Indevus Pharmaceuticals, Inc. (Endo International PLC)
• Original Assignee: Mclean Hospital (Mass General Brigham, Inc.)
• Inventors: Renshaw, Perry F., Lukas, Scott
• Primary Examiner(s): Spivack, Phyllis G.
• Application Number:
  US08/908,997
• Time in Patent Office: 781 Days
• Field of Search: 514/49, 514/812, 514/274
• US Class Current: 514/49
• CPC Class Codes: A61K 31/7068 having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• CPC Class Codes: A61P 25/30 for treating abuse or dependence

Abstract

Disclosed herein is a method for reducing stimulant dependencies in mammals that involves administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, such as CDP-choline.

Claims

1. A method of treating a mammal exposed to a stimulant, comprising administering to said mammal a therapeutically-effective amount of a cytidine-containing compound.

2. The method of claim 1, wherein said stimulant is cocaine.

3. The method of claim 1, wherein said cytidine-containing compound is cytidine.

4. The method of claim 1, wherein said cytidine-containing compound further comprises choline.

5. The method of claim 1, wherein said cytidine-containing compound is CDP-choline.

6. The method of claim 1, wherein said cytidine-containing compound is CDP.

7. The method of claim 1, wherein said mammal is a human.

8. The method of claim 7, wherein said human is a pregnant woman or a child with antenatal exposure to a stimulant.

9. The method of claim 7, wherein said human has a stimulant craving.

10. The method of claim 7, wherein said human has a stimulant dependency.

11. A method of treating stimulant-induced cerebral vasoconstriction sequelae in a mammal, comprising administering to said mammal a therapeutically-effective amount of a cytidine-containing compound.

12. The method of claim 11, wherein said cerebral vasoconstriction results from exposure to cocaine.

13. The method of claim 11, wherein said cerebral vasoconstriction results from exposure to a substance that causes cerebral vasoconstriction.

14. The method of claim 11, wherein said mammal is a human.

15. The method of claim 11, wherein said cytidine-containing compound is cytidine.

16. The method of claim 11, wherein said cytidine-containing compound further comprises choline.

17. The method of claim 11, wherein said cytidine-containing compound is CDP-choline.

18. The method of claim 11, wherein said cytidine-containing compound is CDP.

19. A method of treating a mammal exposed to a stimulant, comprising administering to said mammal a therapeutically-effective amount of a cytosine-containing compound.

20. The method of claim 19, wherein said mammal is a human.

21. The method of claim 19, wherein said human is a pregnant woman or a child with antenatal exposure to a stimulant.

22. The method of claim 19, wherein said human has a stimulant craving.

23. The method of claim 19, wherein said human has a stimulant dependency.

24. A method of treating cerebral vasoconstriction sequelae in a mammal, comprising administering to said mammal a therapeutically-effective amount of a cytosine-containing compound.

25. The method of claim 24, wherein said cerebral vasoconstriction results from exposure to cocaine.

26. The method of claim 24, wherein said cerebral vasoconstriction results from exposure to a substance that causes cerebral vasoconstriction.

27. The method of claim 24, wherein said mammal is a human.